We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Aptinyx Inc. (APTX) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Aptinyx Inc. one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Aptinyx Inc. is one of 1161 companies in the Medical group. The Medical group currently sits at #10 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Aptinyx Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for APTX's full-year earnings has moved 1% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, APTX has moved about 33.7% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 8.2% on average. This means that Aptinyx Inc. is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Molina (MOH - Free Report) . The stock is up 0.5% year-to-date.
Over the past three months, Molina's consensus EPS estimate for the current year has increased 1.1%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Aptinyx Inc. is a member of the Medical - Biomedical and Genetics industry, which includes 540 individual companies and currently sits at #138 in the Zacks Industry Rank. This group has lost an average of 13.1% so far this year, so APTX is performing better in this area.
In contrast, Molina falls under the Medical - HMOs industry. Currently, this industry has 8 stocks and is ranked #102. Since the beginning of the year, the industry has moved -4.3%.
Investors with an interest in Medical stocks should continue to track Aptinyx Inc. and Molina. These stocks will be looking to continue their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Is Aptinyx Inc. (APTX) Outperforming Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Aptinyx Inc. one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Aptinyx Inc. is one of 1161 companies in the Medical group. The Medical group currently sits at #10 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Aptinyx Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for APTX's full-year earnings has moved 1% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, APTX has moved about 33.7% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 8.2% on average. This means that Aptinyx Inc. is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Molina (MOH - Free Report) . The stock is up 0.5% year-to-date.
Over the past three months, Molina's consensus EPS estimate for the current year has increased 1.1%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Aptinyx Inc. is a member of the Medical - Biomedical and Genetics industry, which includes 540 individual companies and currently sits at #138 in the Zacks Industry Rank. This group has lost an average of 13.1% so far this year, so APTX is performing better in this area.
In contrast, Molina falls under the Medical - HMOs industry. Currently, this industry has 8 stocks and is ranked #102. Since the beginning of the year, the industry has moved -4.3%.
Investors with an interest in Medical stocks should continue to track Aptinyx Inc. and Molina. These stocks will be looking to continue their solid performance.